Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En studie av Orelabrutinib hos pasienter med sekundær progressiv multippel sklerose

6. november 2026 oppdatert av: Zenas BioPharma (USA), LLC

En fase 3, randomisert, dobbeltblind, effektivitets- og sikkerhetsstudie som sammenligner Orelabrutinib med placebo hos pasienter med ikke-aktiv sekundær progressiv multippel sklerose

Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with non-active Secondary Progress MS. Patients will be treated for approximately 24 to 60 months, with a minimum treatment duration of 12 months. The study will enroll approximately 990 subjects in a 2:1 randomization (orelabrutinib: placebo), globally.

Studieoversikt

Status

Rekruttering

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with naSPMS. The study will enroll approximately 990 subjects in a 2:1 randomization (orelabrutinib: placebo), globally.

The study consists of the following periods:

  • Screening Period: Up to 4 weeks.
  • Treatment Period: The duration of treatment will vary for individual participants ranging from approximately 24 to 60 months, depending on the time of recruitment. A month is defined as a period of 28 days by convention.
  • Double-blinded (DB) Treatment: All eligible participants will be randomized at 2:1 ratio to accept orelabrutinib QD or placebo during the DB treatment period. The study will be unblinded when all participants in the DB period have reached a minimum treatment duration of 12 months at the time of primary analysis timing cutoff.
  • Open-label (OL) Treatment: Participants with 24-week CDP as assessed by EDSS are eligible for 2-year open-label orelabrutinib treatment.
  • Safety Follow-Up Period: It will last 4 weeks. The safety follow-up period will begin when the participants discontinue from the treatment before the end of the trial for any reasons or complete the trial but do not enter the long-term safety study (LTS) (see below).

All active study participants will have a final end of study (EOS) visit within 4 weeks of the study end date. Participants who are receiving IMP in DB or OL but do not consent to or are not eligible for enrollment in the LTS study, must return for a final safety follow-up visit 4 weeks later. For participants who intend and are eligible to join the LTS, open-label treatment with orelabrutinib will continue and no safety follow-up will occur.

Studietype

Intervensjonell

Registrering (Antatt)

990

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

    • New South Wales
      • Kogarah, New South Wales, Australia, 2217
        • Rekruttering
        • Southern Neurology Suite 2
      • Sovet, Belgia, 1408
        • Rekruttering
        • DCC Neoclinic - Sofia
    • Limburg
      • Overpelt, Limburg, Belgia, 3900
        • Rekruttering
        • MS-Netwerk Limburg - Revalidatie
      • Pleven, Bulgaria, 5800
        • Rekruttering
        • Avis Medica Hospital Pleven
    • Plovdiv
      • Plovdiv, Plovdiv, Bulgaria, 4000
        • Rekruttering
        • Medical Center Nevrocentrum
    • Sofia
      • Sofia, Sofia, Bulgaria, 1680
        • Rekruttering
        • Diagnostic and Consultative Center Convex
      • Sofia, Sofia, Bulgaria, 1510
        • Rekruttering
        • Medical Center Hera EOOD
    • Tarnovo
      • Veliko Tarnovo, Tarnovo, Bulgaria, 5000
        • Rekruttering
        • Medical Center Medica Plus OOD
    • Harju
      • Tallinn, Harju, Estland, 10617
        • Rekruttering
        • Astra clinic (Clinic4U)
    • Arizona
      • Phoenix, Arizona, Forente stater, 85032
        • Rekruttering
        • Arizona Neuroscience Research, LLC
      • Scottsdale, Arizona, Forente stater, 85253
        • Rekruttering
        • Perseverance Research Center, LLC (PRC)
    • California
      • Fullerton, California, Forente stater, 92835
        • Rekruttering
        • Fullerton Neurology and Headache Center
      • Torrance, California, Forente stater, 90502-2006
        • Rekruttering
        • Harbor-UCLA Medical Center - The Lundquist Institute (Los Angeles Biomedical Research Institute (LA BioMed))
      • West Hollywood, California, Forente stater, 90048
        • Rekruttering
        • Regina Berkovich MD, PhD Inc
    • Florida
      • Boca Raton, Florida, Forente stater, 33487
        • Rekruttering
        • SFM Clinical Research, LLC
      • Bradenton, Florida, Forente stater, 34209
        • Rekruttering
        • Nova Clinical Research, LLC
      • Clearwater, Florida, Forente stater, 33761
        • Rekruttering
        • MS and Neuromuscular Center of Excellence
      • Maitland, Florida, Forente stater, 32751
        • Rekruttering
        • Neurology Associates
      • Naples, Florida, Forente stater, 34105
        • Rekruttering
        • Aqualane Clinical Research
      • Tampa, Florida, Forente stater, 33612
        • Rekruttering
        • University of South Florida Department of Neurology - MS Division
    • Indiana
      • Indianapolis, Indiana, Forente stater, 46256
        • Rekruttering
        • Josephson Wallack Munshower Neurology, Pc Suite 225
    • Kansas
      • Kansas City, Kansas, Forente stater, 66160
        • Rekruttering
        • University of Kansas Medical Center
      • Roeland Park, Kansas, Forente stater, 66205
        • Rekruttering
        • KC Research Center, PA Neurology Research Dept
    • Massachusetts
      • Boston, Massachusetts, Forente stater, 02131
        • Tilbaketrukket
        • Boston Clinical Trials
      • Worcester, Massachusetts, Forente stater, 01655
        • Rekruttering
        • University of Massachusetts Memorial Medical Center
    • Michigan
      • Rochester Hills, Michigan, Forente stater, 48307
        • Rekruttering
        • Profound Research LLC at Oakland Neurology Center
    • Missouri
      • St Louis, Missouri, Forente stater, 63110
        • Rekruttering
        • Washington University School of Medicine
    • New Mexico
      • Albuquerque, New Mexico, Forente stater, 87131
        • Rekruttering
        • University Of New Mexico School Of Medicine
    • New York
      • New York, New York, Forente stater, 10029
        • Rekruttering
        • Mount Sinai Medical Center
    • Ohio
      • Columbus, Ohio, Forente stater, 43235
        • Rekruttering
        • The Boster Center for Multiple Sclerosis
      • Columbus, Ohio, Forente stater, 43221
        • Rekruttering
        • The Ohio State University Wexner Medical Center (OSUWMC)
    • Oklahoma
      • Oklahoma City, Oklahoma, Forente stater, 73104
        • Rekruttering
        • OMRF Multiple Sclerosis Center of Excellence
    • South Carolina
      • Greenville, South Carolina, Forente stater, 29605
        • Rekruttering
        • Premier Neurology
    • Tennessee
      • Cordova, Tennessee, Forente stater, 38018
        • Rekruttering
        • Neurology Clinic, P.C.
    • Texas
      • San Antonio, Texas, Forente stater, 78258
        • Rekruttering
        • Lone Star Neurology
      • Sherman, Texas, Forente stater, 75092
        • Rekruttering
        • Texas Institute for Neurological Disorders - Sherman
    • Brest
      • Pordic, Brest, Frankrike, 29609
        • Rekruttering
        • CHU Brest Hospital Cavale
    • Gard
      • Nîmes, Gard, Frankrike, 30029
        • Rekruttering
        • Centre Hospitalier Universitaire de Nimes (CHU) - Hopital Universitaire Caremeau
    • Yveline
      • Poissy, Yveline, Frankrike, 78300
        • Rekruttering
        • Centre Hospitalier Intercommunal (Chi) Poissy-Saint-Germain-En-Laye - Site De Poissy
      • Tbilisi, Georgia, 0114
        • Rekruttering
        • LTD Pineo Medical Ecosystem
      • Tbilisi, Georgia, 0186
        • Rekruttering
        • Raymann, LLC
      • Tbilisi, Georgia, 0159
        • Rekruttering
        • NNLE Jo Ann University Hospital
      • Tbilisi, Georgia, 0186
        • Rekruttering
        • Caucasus Medical Center Ltd
    • K'alak'i T'bilisi
      • Tbilisi, K'alak'i T'bilisi, Georgia, 0114
        • Rekruttering
        • JSC Curatio
    • Saburtalo
      • Tbilisi, Saburtalo, Georgia, 0160
        • Rekruttering
        • MD Georgia Staff Physician MediClub Georgia
    • Athens
      • Cholargós, Athens, Hellas, 15562
        • Rekruttering
        • Metropolitan General Hospital
    • Attica
      • Athens, Attica, Hellas, 11526
        • Rekruttering
        • Errikos Dunant Hospital
    • Chieti
      • Chieti, Chieti, Italia, 66100
        • Rekruttering
        • University G. D'Annunzio of Chieti-Pescara
    • Isernia/Molise
      • Pozzilli, Isernia/Molise, Italia, 86077
        • Rekruttering
        • IRCCS Istituto Neurologico Mediterraneo Neuromed
      • Zagreb, Kroatia, 10 000
        • Rekruttering
        • Klinicki Bolnicki Centar Zagreb-Rebro
    • Kauno
      • Kaunas, Kauno, Litauen, 50161
        • Rekruttering
        • Hospital of Lithuanian University of Health Sciences
      • Lublin, Polen, 20-064
        • Rekruttering
        • Galen Clinic
      • Plewiska, Polen, 62-064
        • Rekruttering
        • Neurologiczny Niepubliczny ZOZ Centrum Leczenia SM Osrodek Badan Klinicznych im. dr n. med. Hanki Hertmanowskiej
      • Poznan, Polen, 15-540
        • Rekruttering
        • Prywatna Lecznica Certus Sp. z o.o.
      • Szczecin, Polen, 70-111
        • Rekruttering
        • EUROMEDIS Osrodek Badan Klinicznych
      • Żory, Polen, 44-240
        • Rekruttering
        • Centrum Medyczne ProNeuro Żory
    • Kuyavian-Pomeranian Voivodeship
      • Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Polen, 85-605
        • Rekruttering
        • Centrum Medyczne INTERCOR Sp. z o.o.
    • Lublin Voivodeship
      • Lublin, Lublin Voivodeship, Polen, 20-601
        • Rekruttering
        • Malva Trials
      • Lublin, Lublin Voivodeship, Polen, 20-064
        • Rekruttering
        • Instytut Naukowo-Badawczy w Lublinie Sp. z o.o.
      • Lublin, Lublin Voivodeship, Polen, 20-064
        • Rekruttering
        • NZOZ Neuromed M. i M. Nastaj Sp.P
    • Lubusz Voivodeship
      • Nowa Sól, Lubusz Voivodeship, Polen, 67-100
        • Rekruttering
        • Twoja Przychodnia Centrum Medyczne Nowa Sól
    • Mazovian
      • Warsaw, Mazovian, Polen, 02-172
        • Rekruttering
        • MTZ Clinical Researcz Powered by pratia
    • Rzeszów
      • Rzeszów, Rzeszów, Polen, 35-323
        • Rekruttering
        • Nmedis sp. z o.o.
    • Silesian Voivodeship
      • Katowice, Silesian Voivodeship, Polen, 40-081
        • Rekruttering
        • Centrum Medyczne Pratia Katowice
      • Katowice, Silesian Voivodeship, Polen, 40-571
        • Rekruttering
        • MA-LEK Clinical Sp. z o.o.
      • Katowice, Silesian Voivodeship, Polen, 40-584
        • Rekruttering
        • NZOZ Novo Med
    • Upper Silesia
      • Katowice, Upper Silesia, Polen, 40-686
        • Rekruttering
        • Neuro Medic Clinic
    • Wielkopolska
      • Poznan, Wielkopolska, Polen, 61-853
        • Rekruttering
        • Nzoz Neuro-Kard Ilkowski I Partnerzy Spolka Partnerska Lekarzy
      • Poznan, Wielkopolska, Polen, 60-324
        • Rekruttering
        • Twoja Przychodnia PCM
    • Łódź Voivodeship
      • Lodz, Łódź Voivodeship, Polen, 91-743
        • Rekruttering
        • PRO SALUS Sp. z o.o. sp.k.
      • Lodz, Łódź Voivodeship, Polen, 90-324
        • Rekruttering
        • Centrum Neurologii Krzysztof Selmaj
      • Guaynabo, Puerto Rico, 00969
        • Rekruttering
        • Caribbean Center for Clinical Research
    • Constanța County
      • Constanța, Constanța County, Romania, 900123
        • Rekruttering
        • Spital Clinic CF Constanta
    • Suceava
      • Radauti, Suceava, Romania, 725400
        • Rekruttering
        • Spitalul Municipal Sf. Doctori Cosma si Damian Radauti
      • Kragujevac, Serbia, 34000
        • Rekruttering
        • University Clinical Centre of Kragujevac
      • Niš, Serbia, 18000
        • Rekruttering
        • Clinic of Neurology - Clinical Center Nis
    • Belgrade
      • Belgrade, Belgrade, Serbia, 11000
        • Rekruttering
        • University Clinical Centre of Serbia
    • A Coruña
      • A Coruña, A Coruña, Spania, 15006
        • Rekruttering
        • Complejo Hospitalario Universitario A Coruña
    • Galicia
      • Vigo, Galicia, Spania, 36312
        • Rekruttering
        • Hospital Alvaro Cunqueiro
    • Madrid
      • Madrid, Madrid, Spania, 28007
        • Rekruttering
        • Hospital Gregorio Marañon
      • Majadahonda, Madrid, Spania, 28222
        • Rekruttering
        • Hospital Universitario Puerta de Hierro de Majadahonda
    • Málaga
      • Málaga, Málaga, Spania, 29016
        • Rekruttering
        • Vithas Hospital Parque San Antonio
    • Seville
      • Castilleja de la Cuesta, Seville, Spania, 41950
        • Rekruttering
        • Hospital Vithas Nisa Sevilla
      • Choceň, Tsjekkia, 56501
        • Rekruttering
        • NEUROHK, s.r.o.
      • Jihlava, Tsjekkia, 58601
        • Rekruttering
        • Regional Hospital Jihlava
    • Hesse
      • Bad Homburg, Hesse, Tyskland, 61348
        • Rekruttering
        • Zentrum fur klinische Forschung Dr.Scholl GmbH
      • Ivano-Frankivsk, Ukraina, 76943
        • Rekruttering
        • Neuro Global
      • Lviv, Ukraina, 79010
        • Rekruttering
        • Lviv National Medical University named after Danylo Galytskiy
      • Vinnytsia, Ukraina, 21009
        • Rekruttering
        • Medical Clinical Investigational Center of Medical Center LLC Health Clinic
    • Chernivtsi Oblast
      • Chernivtsi, Chernivtsi Oblast, Ukraina, 58023
        • Rekruttering
        • Regional Municipal Non-commercial Enterprise Chernivtsi Emergency Medical Hospital
    • Ivano-Frankivs'k Oblast
      • Ivano-Frankivsk, Ivano-Frankivs'k Oblast, Ukraina, 76018
        • Rekruttering
        • CNE City Clinical Hospital #1 of Ivano-Frankivsk council
    • Lviv Oblast
      • Lviv, Lviv Oblast, Ukraina, 79000
        • Rekruttering
        • Limited Liability Company Medical Center Neuroclinic
      • Lviv, Lviv Oblast, Ukraina, 79029
        • Rekruttering
        • Limited Liability Company "Neurofocus"
      • Budapest, Ungarn, 1145
        • Rekruttering
        • National Institute of Clinical Neurosciences
      • Tatabánya, Ungarn, 2800
        • Rekruttering
        • Komarom-Esztergom Varmegyei Szent Borbala Korhaz
    • Komarom-Esztergom Vamegye
      • Esztergom, Komarom-Esztergom Vamegye, Ungarn, 2500
        • Rekruttering
        • Valeomed Kft.

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 60 år (Voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. 18 to 60 years of age, inclusive, at the time of signing the informed consent.
  2. Participant must have a previous diagnosis of RRMS in accordance with 2024 McDonald criteria
  3. Participant must have a current diagnosis of SPMS in accordance with the clinical course criteria revised in 2013
  4. Participant must have documented evidence of disability progression independent of clinical relapse observed during the 24 months before screening. A written summary of the clinical evidence of disability progression must be discussed and aligned between the Investigator and the Sponsor's dedicated qualified person(s).
  5. Absence of clinical relapses for at least 24 months.

Exclusion Criteria:

  1. The patient has been diagnosed with primary progressive MS (PPMS) according to 2024 McDonald diagnostic criteria
  2. Immunologic disorder other than MS or any other conditions requiring corticosteroid therapy.
  3. History or current diagnosis of other neurological disorders that may mimic MS
  4. History or current diagnosis of progressive multifocal leukoencephalopathy
  5. Active, clinically significant viral, bacterial, or fungal infection
  6. History of any other significant active medical condition
  7. History of suicidal behavior within 6 months prior to Screening
  8. Any prior history of malignancy
  9. Patients on anticoagulation, or antiplatelet therapy
  10. Patients took strong/moderate CYP3A inhibitors or strong/moderate CYP3A inducers within 14 days
  11. Clinically significant laboratory abnormalities at Screening.
  12. Vaccination with live or live-attenuated virus vaccine within 1 month prior to Screening
  13. History of alcohol abuse or alcohol use disorder or other drug abuse within 12 months prior to screening.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Orelabrutinib Group

Orelabrutinib PO daily

Orelabrutinib orally

Placebo komparator: Placebo Group

Placebo PO daily

Placebo orally

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Time to onset of confirmed disability progression (CDP) events, confirmed over at least 24 weeks
Tidsramme: Up to approximately 120 weeks

Expanded disability status scale (EDSS) score increase ≥ 1.0 point from baseline when the baseline score is ≤ 5.0, or ≥ 0.5 points from baseline when the baseline score is > 5.0

Up to approximately 120 weeks

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
12 Week CDP
Tidsramme: Up to approximately 120 weeks

Time to onset of CDP events on EDSS, confirmed over at least 12 weeks

Up to approximately 120 weeks
T2 lesions on MRI
Tidsramme: Up to approximately 120 weeks

The total number of new or enlarging T2 lesions on MRI scans of the brain

Up to approximately 120 weeks
24-week CDP-9-hole Peg Test
Tidsramme: Up to approximately 120 weeks

Time to onset of CDP events on 9-hole Peg Test (9HPT), defined as ≥ 20% increase on 9HPT from baseline, confirmed over at least 24 weeks

Up to approximately 120 weeks
24-week CDP-T25FWT
Tidsramme: Up to approximately 120 weeks

Time to onset of CDP events on Timed 25-Foot Walk Test (T25FWT), defined as ≥ 20% increase on T25FWT from baseline, confirmed over at least 24 weeks

Up to approximately 120 weeks
24-week CDI
Tidsramme: Up to approximately 120 weeks

Time to onset of confirmed disability improvement (CDI) events on EDSS, defined as ≥ 1.0-point decrease on the EDSS score from baseline when the baseline score is ≤ 5.0, or ≥ 0.5 points from baseline when the baseline score is > 5.0, confirmed over at least 24 weeks

Up to approximately 120 weeks
24-week CDI-9HPT
Tidsramme: Up to approximately 120 weeks

Time to onset of CDI events on 9HPT, defined as ≥ 20% decrease on the 9HPT score from baseline, confirmed over at least 24 weeks

Up to approximately 120 weeks
24-week CDI-T25FWT
Tidsramme: Up to approximately 120 weeks

Time to onset of CDI events on T25FWT, defined as ≥ 20% decrease on the T25FWT score from baseline, confirmed over at least 24 weeks

Up to approximately 120 weeks
Symbol Digit Modalities Test
Tidsramme: Up to approximately 120 weeks

The change in cognitive function as assessed by Symbol Digit Modalities Test (SDMT) from baseline to each scheduled visit

Up to approximately 120 weeks
Annualized relapse rate
Tidsramme: Up to approximately 120 weeks

Annualized relapse rate (ARR) during the study period assessed by protocol-defined adjudicated relapses

Up to approximately 120 weeks
To evaluate the safety and tolerability of orelabrutinib
Tidsramme: Up to approximately 120 weeks

Safety as assessed by the nature, severity, and incidence of adverse events (AEs) (graded according to National Cancer Institute-Common Terminology Criteria for AEs, NCI-CTCAE version 5.0);

Up to approximately 120 weeks

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

23. mars 2026

Primær fullføring (Antatt)

1. juni 2030

Studiet fullført (Antatt)

1. juli 2030

Datoer for studieregistrering

Først innsendt

18. desember 2025

Først innsendt som oppfylte QC-kriteriene

19. desember 2025

Først lagt ut (Faktiske)

23. desember 2025

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

12. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

6. november 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • ZB020-03-002

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .